Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.

Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol. 2020 02; 95(2):E34-E35.

View in: PubMed

collapse authors with profiles